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Abstract
BACKGROUND: Many models of assessing radiopharmaceuti-
cal kinetics for dosimetry have been developed, starting from 
the formula of Marinelli. They are either inaccurate or require 
taking multiple patient uptake measurements.
MATERIAL AND METHODS: Radiotracer behavior is ap-
proached to a modified Bateman equation (“biphasic model”). 
The calculated effective half time, maximum uptake and the 
cumulated uptake according to the biphasic model is compared 
to the values obtained with the most popular Marinelli’s method 
(“simplified model”). The calculations can be performed by free 
online-accessible software on the site: www.nuk.bieganski.org 
(“Calculator”).
RESULTS: Using of the software allows a direct comparison of 
the obtained effective half times according to both, the simpli-
fied and the biphasic, models. Further errors can come from 
imprecise measure of the maximum uptake value (especially, 
when the time of the measurement differs from the true point 
of the maximum uptake) and from neglecting of the ascending 
branch of the time-uptake curve. It is possible to compare the 
cumulated uptake values according to both models (“correction 
factor”). The results can be combined with the widely known 
formula of Marinelli. The operations require only one additional 
uptake measurement, which could be performed shortly after 
the i.v. administration of the radiotracer, i.e., during the same 
visit of the patient.
CONCLUSION: The proposed theoretic model could be verified 
practically for some i.v.-administered radiopharmaceuticals.
KEY words: effective half time, radiotracer uptake, 
radionuclide therapy, computation
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Background
The calculation of radioiodine activity for treatment of thyroid 
disorders according to Leonidas D. Marinelli (1906–1974) [1, 2] 
was the first attempt to optimize radionuclide therapy. Therapy 
of thyroid disorders with iodine-131, as the most common one, 
frequently serves as the paradigm of radionuclide therapy.
The dose of corpuscular radiation delivered to a target during 
radionuclide therapy can be expressed as:
, where:
D: focal radiation dose,
Emean: mean energy of particles emitted per one radioactive dis-
integration,
m: target mass,
A: administered activity of the nuclide,
U(t): uptake of the radionuclide in the target as a function of time. 
The integral of the function multiplied by A equals the total number 
of radioactive disintegrations occurring in the organ (also referred 
to as “cumulated activity” or “time integrated activity”). It is as-
sumed that:
 — the range of the particles released by the decaying nuclei 
is much shorter than the diameters of the target structure;
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 — there is no radiation delivered to the target from outside;
 — there is no significant influence of the radiation emitted on the 
kinetics of the radiotracer and on the target’s mass.
Precise determination of the target activity/uptake in function 
of time is frequently a challenge. The primary model [1, 2], further 
referred to as “simplified model”, takes into consideration only the 
maximum uptake of the radionuclide and the effective half time; 
only few (even two) uptake tests are necessary for calculation of 
the function which can be mathematically expressed as:
, where:
Umm: the measured maximum uptake value (i.e., the highest ob-
tained value of uptake, frequently lower than the true maximum),
t: the time elapsed,
Tef: the effective half-time of the radiotracer in the organ,
Ut(sim): the uptake in the time t according to the simplified model.
The procedure of the simplified model can be further modified 
with either:
 — determination of some typical (mean) parameters for a given 
kind of radionuclide therapy [3, 4], or
 — more accurate determination of these parameters in a given 
patient [5, 6].
In the former methods, some kinetic parameters have been 
determined experimentally, what allows additional reducing of the 
number of the measurement procedures even to one. Although 
the results reflect a statistical mean, not each patient equals such 
a standard. In the author’s experience, there is known a female 
patient suffering from Graves disease with the measured ra-
dioiodine effective half time in the thyroid of less than 1 day; if 
a “standard effective half time” had been used for the calculation 
of the administered activity (above 4 days [4]), the method would 
have underestimated this activity more than four-fold. The latter 
methods are more personalized, but need numerous tests to be 
performed, what in turn causes logistic problems.
The purpose of the study is to discuss a model which potentially 
combines a higher accuracy in determination of the parameters of 
the time-uptake function with a lower number of patient uptake tests. 
Self-designed, free-accessible programs for the calculations are 
accessible on the web-site of the Department of Nuclear Medicine in 
Grudziądz, Poland: http://www.nuk.bieganski.org/ (the tool was de-
scribed earlier in the reference [7]). The programs are accessible in 
two languages: Polish and English; unless one’s native is Polish, the 
User should first click the English flag (right upper corner) and then 
proceed to Calculator (the last green button, left side). This study 
concentrates on two algorithms: “Kinetic modeling I” and “Kinetic 
modeling II” (option 4 and 5, respectively) in “Calculations related 
to nuclear medicine”.
Materials and methods
A biphasic model of radiotracer behavior was developed. It 
was assumed that:
 — the radiotracer is injected i.v. as a bolus;
 — its concentration in blood decreases exponentially in function 
of time;
 — its influx rate into the target is proportional to its concentration 
in blood, and
 — its efflux rate from the target is proportional to its concentration 
in the target (follows the rules of the first order kinetics).
In such a case, the uptake of the radiotracer in the target in 
function of time may be approached by the Bateman [8] equation 
describing the quantity of the second nuclide in the radioactive 
chain [9]. After appropriate modification, this formula is:
, where:
Ut(biph): the uptake of the radiotracer according to the biphasic model,
Tef: the effective half-time of the radiotracer in the target,
Ta: the half time of the influx of the radiotracer into the target,
F: a proportionality factor. It is also assumed that 
Ta < Tef.
Integration of the uptake functions according to both (simplified 
and biphasic) models allows to get the formulas for “time-integrated 
uptake” or “cumulated uptake”. Thus, one gets:
 and hence
,
and
 and hence
for the simplified and biphasic model, respectively. After divi-
sion of the cumulated uptake according to the biphasic model 
by the cumulated uptake according to the simplified model, one 
receives the ratio, by which the cumulated activity in the biphasic 
model exceeds the cumulated activity in the simplified one:
.
This parameter is further referred to as correction factor, Cf.
The next issue one needs to address is to find the parameters of 
the equations for both models, particularly for the biphasic one, i.e., 
Tef, Ta and F. The program “Kinetic modeling I” allows to determine 
the effective half time according to the earlier known procedure. 
Logarithmized uptake values are plotted on a chart against the 
time values, then a straight line is created with the method of least 
squares:
log10 Ut = a · t + b,
where a and b are the calculated parameters of the straight line. 
Optimally, the two points should lie far one from another and far 
after the peak of the curve. The slope a of the generated line 
is related to the Tef:
.
An innovation of the program offers an additional possibility to 
successively approximate the Ta and F for the biphasic model; the 
mathematical details are discussed in the Appendix.
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The program “Kinetic modeling II” allows determining of all three 
parameters in a semi-automated manner by numerical analysis. 
Three measurement points are necessary for proper functioning 
of the program; optimally: the first — before the expected peak 
(shortly after the activity administration), the second one in a time 
close to the expected peak, and the third one well after the peak. 
The mathematical details are discussed in the Appendix.
Knowledge of the correction factor allows introducing suitable 
modifications to the Marinelli’s formula and thus using the most 
common and the simplest existing algorithm for calculation of the 
therapeutic activity; there is no necessity to introduce a completely 
new formula:
, where:
A: the activity of a radionuclide required for a therapy,
D: the intended focal radiation dose,
m: the target mass,
Umm: the measured maximum uptake of the radiopharmaceutical,
Tef: the effective half time,
Emean: the mean kinetic energy of the emitted particles per one 
radioactive disintegration (for I-131: 181.9 keV),
Cf: correction factor (this part of the formula is important, when the 
correction factor is different from one).
Results
Theoretical uptake-curves which fulfill the considered condi-
tions of radiopharmaceutical behavior have been created. They 
served for examining of the possible values of the correction factor.
If the measured maximum uptake (Umm) is equal to the peak 
(i.e., the test is performed exactly in the time of peak), the correc-
tion factor (Cf) increases along with the increasing ratio Ta/Tef. The 
increase is more pronounced for low Ta/Tef-ratios, then the trend 
slows down and reaches as much as e (~2.7183) for Ta equal to 
Tef. For instance, if the Ta equals half of the Tef, the Cf is 2.0; it indi-
cates that the cumulated uptake is underestimated two-fold in the 
simplified model as compared to the biphasic one. If additionally 
Umm is lower than the true peak, the cumulative error increases pro-
portionally. The issue is illustrated in Figure 1.
Discussion
Because of its logistic advantages, application of the simplified 
model is the most popular approach to personalized dosimetry. In 
its simplest version, only two uptake tests are necessary: the first 
around the expected peak and the second some time thereafter.
Such approach, although very convenient, is prone to at least 
three sources of error:
1. Overestimation of the effective half time; this inaccuracy is par-
ticularly pronounced, when the first measured value is placed 
too early on the time-uptake curve. It may result in an overes-
timation of the cumulated uptake.
2. Underestimation of the maximum uptake, when the measured 
maximum value does not correspond to the true peak of the 
curve; it may result in an underestimation of the cumulated uptake.
3. Neglecting of the ascending branch of the time-uptake curve; 
it results in an underestimation of the cumulated uptake.
The effective half time could be theoretically better approached 
(but never perfectly calculated) by the simplified method with in-
creasing number of the measurements; however, such a calculation 
would never be perfect. The fact is an implication of the mathematical 
algorithm itself. Using the biphasic function should theoretically give 
the effective half time, whose value is not biased in such a way. Sepa-
rate performing of the calculations with both programs (i.e., “Kinetic 
modeling I” and “Kinetic modeling II”) allows a direct comparison of 
the effective half times calculated by each of these models.
The program “Kinetic modeling II” tries to combine a low num-
ber of patient tests with a higher precision of the results. The first 
test should be performed preferably in a time point between the 
administration of the radiopharmaceutical and the peak; in most 
cases, it could take place even during the same visit of the patient 
as the administration. The second and third uptake value should be 
preferably measured near the expected peak and some time after 
the peak, respectively. Thus, the procedure of uptake tests would 
not be much more engaging than in the simplified model.
Both the programs give also additional information about the 
theoretically calculated peak, i.e., the time and the percentage 
of the maximum uptake of the radiotracer. This could be useful 
for some purposes, possibly also for a further optimization of the 
administration-measurement procedure.
Figure 1. Correction factor (Cf, abscissa) as a function of the quotient of the half-time of the radiotracer influx and the effective half time (Ta/Tef, 
ordinate). It is assumed that the measured maximum uptake equals the true peak of the curve (black line). For comparison, the grey line reflects  
the Cf in a case, if the measured maximum uptake is lower by a factor of 5% than the true one (for example: 28.5% instead of 30%)
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The biphasic model comes from pure mathematical considera-
tions. Actually, biologic processes differ from the ideal mathematical 
ones to some extent. The biphasic model could reflect the uptake 
of a radiotracer in a target organ, when some kinetic criteria are 
fulfilled (listed at the beginning of “Material and methods”). Radioio-
dine therapy of the thyroid disorders and palliative therapy of bone 
metastatic lesions after i.v. injection of radiopharmaceuticals are 
candidates which probably well approach to these criteria. Some 
types of receptor radionuclide therapy, despite frequently occur-
ring saturation effects, also could be regarded as approaching the 
model to a satisfactory degree. A therapy after oral administration 
of a radiotracer could approach this model to a degree less than 
satisfactory.
Conclusion
The proposed model of calculation of the correction for the 
dosimetry seems to deliver the results in a relatively simple way. 
Its practical testing can be considered.
Appendix. Mathematical operations  
used in these programs
A. Kinetic modeling I
First, user-selected logarithmized uptake values are ap-
proached to a straight line by linear regression:
log10 Ut = a · t + b,
hence the effective half time is calculated (see the text for details).
For additional approximation of the Ta and F (biphasic model), 
an uptake test value (time and uptake) made chronologically before 
the maximum measured uptake is chosen (t1 and U1). A combined 
formula is constructed:
,
where tlast and Ulast are uptake values of the (chronologically) last 
test. In the combined formula, the Ta-value is iteratively so modified 
that the obtained uptake-value gradually approximates the true 
(measured) one (U1). The User may then optionally modify the 
values obtained by a trial and error method.
B. Kinetic modeling II
Three uptake tests are entered. Thus, one receives three pairs of 
uptake values (time and uptake): t1, U1, t2, U2, t3, U3. For each pair, 
an equation time-uptake (according to the biphasic model) is con-
structed; hence, one obtains a system of three equations with three 
unknowns (Tef, Ta and F):
Since there are exponential equations, it is impossible to solve 
the system using a simple analytical method. An iterative method 
must be applied instead.
At the beginning, the second equation is solved for F. This F 
is substituted into the first equation forming a combined one:
.
Then, a user-defined range of Tef, in which the true Tef is sought, 
is divided by 400; in this way, the Tef-progression is set. From the up-
per limit of Tef, the Tef-progression is successively subtracted till the 
Tef reaches the lower limit. Thus, the temporary Tef-value is defined 
each time (i.e., Tef(i), where the i ranges from 1 to 400).
Then, for each Tef(i), the Ta(i) value (within a range lower than Tef(i)) 
solving the combined equation is iteratively sought; sometimes, it 
is possible to find the Ta(i) only for some Tef(i). Thus, a series of till 
400 pairs Tef(i) and Ta(i) is obtained. Within this series, there is one 
pair, which approaches the sought solution.
Afterwards, all the equations in the system are solved for F, 
delivering till 400 sets of F1(i), F2(i) and F3(i):
                    
Thus, for each Tef(i) and Ta(i) pair found, three F-values (F1(i), F2(i) 
and F3(i)) are calculated. The sought solution (the set of values: F, 
Tef and Ta) is this one, for which all F (F1(i), F2(i) and F3(i)) are the same 
(ideally), or for which the differences are minimal. The expected er-
ror of Tef arises from the Tef-progression. By further narrowing of the 
user-defined Tef-range, one is able to receive a set of solutions with 
a lower expected error.
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